|
GM. This is The Financial Darwin Awards, the support group your portfolio didn't know it needed. Wednesday flipped the script on the last three days. Moderna surged 176.97% on one trial readout. Treasury yields fell after a buyback announcement, and Target beat estimates and got sold anyway. Four people were built for a market that kept doing the opposite of what they expected. They lost $37,677 between them, and every single one of them was on the right side of a narrative and the wrong side of the tape. The traders are composites. The moves are not. Here's what we've got today:
THIS WEEK'S DAMAGE REPORT 📊
The first number is the sum of the four stories below. The second is real: Moderna closed Wednesday at $174.38, up 176.97% on positive Phase 3 melanoma vaccine data with Merck, taking its market cap from $25 billion to $69 billion in one session.
DARWIN AWARD OF THE WEEK 🏆 Every issue we crown the single worst financial decision on the internet. This week it was a bet against a coin flip, sized like it was not one. Here's the setup. Moderna has been a popular short for a long time. Covid vaccine demand faded years ago, and the bear case wrote itself. u/dead_money_thesis had been short the stock on exactly that thesis, certain the company had nothing left to surprise anyone with. On Wednesday, Moderna and Merck released positive Phase 3 data for a personalized melanoma vaccine paired with Merck's Keytruda. The stock did not drift higher on the news. It surged 176.97% in a single session, to $174.38, on volume about eighteen times its three month average. His short is down $17,827, and the stock is still up there. He was not wrong that the old thesis was tired. He was wrong that tired means finished.
Here's the thing. Being short a company for a real reason does not immunize you against a real trial readout. A stock with a fading old thesis can still have a completely unrelated new one, and it does not send a memo first. The most crowded short in the world is still just a bet, and a binary catalyst does not check how many people agree with you. Consensus is not a hedge. It is just a lot of people about to be wrong at the same time.
THIS WEEK'S CASUALTIES 💀 Not everybody can be Darwin Award of the week. These three gave it a real shot. Let's run through the tape. Casualty #1: The Sold-the-Beat Guy u/margin_of_safety_lol bought Target calls expiring Friday, expecting a strong quarter to send the stock higher. He got the strong quarter. Sales rose 5.3% to $26.5 billion, and the company raised its full year guidance. The stock fell 3.01% anyway, to $147.89, on volume more than twenty times its average. Some of the earnings beat came from a one time tariff refund, and traders apparently cared more about that detail than he did. His calls are down $5,800, most of the premium he paid. A beat is a fact. What the market decided to do with that fact was always a separate question.
Casualty #2: The Higher Forever Guy u/yields_only_go_up was short a long duration Treasury position, positioned for the 30 year yield to keep climbing after Monday's two decade high. On Wednesday, the Treasury Department said it would at least double buybacks of long dated government debt. Yields reversed hard. The 10 year fell 5 basis points to 4.65%, and the 30 year dropped 9 basis points to 5.19%, down from its highest level since 2007 earlier in the week. His position is down $10,200, seventeen percent of the $60,000 he had riding on yields not reversing. The moves in yield terms were small. The leverage on his trade was not, and it does not care how many basis points were involved.
Casualty #3: The Gold Bubble Guy u/gold_is_a_bubble_still shorted gold miner shares, certain the rally in gold had gone further than the fundamentals supported. Retail investors disagreed, aggressively. Gold miner ETFs are up more than 20% over the past month, and one fund alone pulled in $419 million from retail buyers in August, the strongest month since February. The logic is not complicated. Miners get leveraged exposure to the metal, since revenue rises with the gold price while a lot of their costs do not move nearly as fast. His short is down $3,850 and the retail inflows have not slowed down. Calling a top on a rally that retail has decided to fund is a specific kind of confidence.
THIS WEEK BY THE NUMBERS 📊 We track the data because the data is funnier than anything we could make up.
Every one of this week's four had a thesis that was reasonable and a market that disagreed anyway. Being reasonable is not the same as being positioned for the version of Wednesday that actually happened.
BITE-SIZED COPIUM FOR THE ROAD 🍪 The best part of any loss thread isn't the screenshot. It's the comments section. Here are this week's greatest hits.
Translation: everybody had a reasonable argument. Nobody had a plan for being reasonable and wrong at the same time.
DUMB MEMES 🤣 Every newsletter needs a meme section. Ours just hits different when the thing that broke was the consensus everyone agreed on.
POV: the most crowded short in the room just got un-crowded
u/margin_of_safety_lol, still rereading the footnotes If you laughed, you're coping. If you didn't laugh, go check what your most confident position would do to a binary surprise. See you next issue. Different mechanisms. Same missing size limit. Traders and P&L screenshots are satirical composites. Market data, prices and yield levels are real and dated August 19 to 20, 2026. Not financial advice. Obviously. Look at us. Stay liquid, |
He shorted the most obvious dead money stock in biotech. It was not dead.
A 177 percent single day squeeze, a beat that got sold anyway, and a bond trade undone by one Treasury announcement.
